A special remark is made to near-infrared photoimmunotherapy directed at CD44 and CD133, which are not only considered markers of CSCs in breast cancer and glioblastoma but also in HNSCC (Kobayashi and Choyke, 2019). This evidence concerns the gene PROM1 and glioblastoma.